Live attenuated HIV as a vaccine for AIDS: Pros and cons

Seminars in Virology

Volumn 7, Issue 2, 1996, Pages 147-155

  Ruprecht, Ruth M ^a,b   Baba, Timothy W ^a,b,c   Li, An ^a,b   Ayehunie, Seyoum ^a,b   Hu, Yuwen ^a   Liska, Vladimir ^a,b   Rasmussen, Robert ^a,b   Sharma, Prem L ^b,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Attenuated live retrovirus vaccines; Avirulent viruses; Correlates of retroviral immunity; Replication impaired viruses; Threshold hypothesis

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CARCINOGENESIS; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MACACA; MURINE LEUKEMIA VIRUS; NONHUMAN; PATHOGENICITY; RISK; SIMIAN IMMUNODEFICIENCY VIRUS; VERTICAL TRANSMISSION; VIRULENCE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MURINAE; MURINE LEUKEMIA VIRUS; PRIMATES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0030003427     PISSN: 10445773     EISSN: None     Source Type: Journal    
DOI: 10.1006/smvy.1996.0019     Document Type: Article

References (51)

1. Clavel F, Hoggan MD, Willey RL, Strebel K, Martin MA, Repaske R (1989) Genetic recombination of human immunodeficiency virus. J Virol 63:1455-1459
2. Kishi M, Tokunaga K, Zheng YH, Bahmani MK, Kakinuma M, Nonoyama M, Lai PK, Ikuta K (1995) Superinfection of a defective human immunodeficiency virus type 1 provirus-carrying T cell clone with vif or vpu mutants gives cytopathic virus particles by homologous recombination. AIDS Res Human Retrovir 11:45-53
3. Robertson DL, Sharp PM, McCutchan FE, Hahn B (1995) Recombination in HIV-1. Nature 374:124-126
4. Murphy BR, Chanock RM (1990) Virology (Fields BN, Knipe DM, Chanock RM, Hirsch MS, Melnick JL, Monath TP, Roizman B, eds) pp 483-502. Raven Press, New York
5. Sabin AB (1985) Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 151:420-436
6. Baba TW, Jeong YS, Penninck, D, Bronson R, Greene MF, Ruprecht RM (1995) Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820-1825
7. Ruprecht RM, Baba TW, Greene MF (1995) Attenuated vaccines for AIDS? The Lancet 346:177-178
8. Ruprecht RM, Baba TW, Liska V, Bronson R, Penninck D, Greene M (1995) 'Attenuated' SIV in macaque neonates. AIDS Res Hum Retroviruses 12:459-460
9. Novembre FJ, Saucier MM, Anderson DC, Klumpp SA, Swenson RB, Brodie AR, McClure HM (1995) Development of AIDS in a chimpanzee infected with HIV-1. 13th Annual Symposium on Non Human Primate Models for AIDS, Monterey, CA, 1995, p243
10. Daniel MD, Letvin NL, King NW, Kannagi M, Sehgal PK, Hunt RD, Kanki PJ, Essex M, Desrosiers RC (1985) Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 228:1201-1204
11. Report of a WHO informal consultation on animal models for evaluation of drugs and vaccines for HIV infection and AIDS; 1990 Meeting report, Ruprecht RM, rapporteur. Biologicals 18:225-233
12. Desrosiers RC (1990) The simian immunodeficiency viruses. Annu Rev Immunol 8:557-578
13. Letvin NL, Daniel MD, Sehgal PK, Desrosiers RC, Hunt RD, Waldron LM, MacKey JJ, Schmidt DK, Chalifoux LV, King NW (1985) Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science 230:71-73
14. Friend C (1959) Immunological relationships of a filterable agent causing leukemia in mice (adult). I. Neutralization of infectivity by specific antiserum. J Exp Med 109:217-228
15. Fink MA, Rauscher FJ (1964) Immune reactions to a murine leukemia virus. I. Induction of immunity to infection with virus in the natural host. JNCI 32:1075-1082
16. Hunsmann G, Schneider J, Schulz A (1981) Immunoprevention of Friend virus-induced erythroleukemia by vaccination with viral envelope glycoprotein complexes. Virology 113:602-612
17. Bayer H, Hunsmann G (1987) Synthetic vaccines against Friend murine leukaemia virus-induced erythroleukaemia: in vivo and in vitro studies with synthetic oligopeptides and sequence-specific antisera. J Gen Virol 68:515-22
18. Earl PL, Moss B, Morrison RP, Wehrly K, Nishio J, Chesebro B (1986) T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science 234:728-731
19. Morrison RP, Earl PL, Nishio J, Lodmell DL, Moss B, Chesebro B (1987) Different H-2 subregions influence immunization against retrovirus and immunosuppression. [Letter]. Nature 329:729-732
20. Sachs L (1962) Transplantability of an x-ray-induced and a virus-induced leukemia in isologous mice inoculated with a leukemia virus. JNCI 29:759-764
21. Mayyasi SA, Moloney JB (1967) Induced resistance of mice to a lymphoid strain of leukemia virus (Moloney). Cancer 20:1124-1130
22. Ruprecht RM, Chou T-C, Chipty F, Gama Sosa MA, Mullaney S, O'Brien L, Rosas D (1990) Interferon-α and 3′-azido-3′-deoxythymidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure. J Acquir Immune Defic Syndr 3:591-600
23. Ruprecht RM, Mullaney S, Bernard LD, Gama Sosa MA, Hom RC, Finberg RW (1990) Vaccination with live retrovirus: The nature of the protective immune response. Proc Natl Acad Sci 87:5558-5562
24. Weiss R, Teich N, Varmus H, Coffin J (eds) (1984) RNA tumor viruses, 2nd ed. Cold Spring Harbor Laboratory, New York
25. + immune T cells. J Virol 65:220-224
26. Marthas ML, Sutjipto S, Higgins J, Lohman B, Torten J, Luciw PA, Marx PA, Pedersen NC (1990) Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol 64:3694-3700
27. Lohman BL, McChesney MB, Miller CJ, McGowan E, Joye SM, Van Rompay KKA, Reay E, Antipa L, Pedersen NC, Marthas ML (1994) A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol 68:7021-7029
28. Kestler HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC (1991) Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651-662
29. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC (1992) Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941
30. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ (1995) Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345:1342-1344
31. Garcia JV, Miller AD (1991) Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350:508-511
32. Gama Sosa MA, DeGasperi R, Kim Y-S, Fazely F, Sharma P, Ruprecht RM (1991) Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. AIDS Res Hum Retroviruses 7:859-860
33. Aiken C, Konner J, Landau NR, Lenburg ME, Trono D (1994) Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76:853-864
34. Trono D (1995) HIV accessory proteins: leading roles for the supporting cast. Cell 82:189-192
35. Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB (1994) The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 179:101-113
36. Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD (1994) The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med 179:115-123
37. Aiken C, Trono D (1995) Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 69:5048-5056
38. Desrosiers R, Daniel M, Lifson J, Arthur L (1995) Infection of chimpanzees with attenuated HIV-1 deletion mutants. 10th Cent Gardes Meeting, Paris, France, 23-25 October 1995, p.4
39. Gibbs JS, Regier DA, Desrosiers RC (1994) Construction and in vitro properties of SIV mutants with deletions in nonessential genes. AIDS Res Human Retroviruses 10:607-616
40. Wyand MS, Manson K, Desrosiers RC, Conference on Advances in AIDS Vaccine Development: 1994, 7th Annual Meeting of the National Cooperation on Vaccine Development Groups for AIDS, Reston, VA, 6 to 10 November 1994 (Division of AIDS-National Institute of Allergy and Infectious Diseases, Bethesda, MD), p. 109
41. Ruprecht RM, Bronson R (1994) Chemoprevention of retroviral infection: Success is determined by virus inoculum strength and cellular immunity. DNA Cell Biol 13:59-66
42. Travers K, Mboup S, Marlink R, Gueye-Ndiaye A, Siby T, Thior I, Traore I, Dieng-Sarr A, Sankale J-L, Mullins C, Ndoye I, Hsieh C-C, Essex M, Kanki P (1995) Natural protection against HIV-1 infection provided by HIV-2. Science 268:1612-1615
43. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh C-C, Dia MC, Gueye E-H, Hellinger J, Gueye-Ndiaye A, Sankale J-L, Ndoye I, Mboup S, Essex M (1994) Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265:1587-1590
44. Vicenzi E, Poli G (1994) Ultraviolet irradiation and cytokinesas regulators of HIV latency and expression. Chem Biol Interact 91:101-109
45. Luciw PA, Shaw KES, Marthas ML (1995) Importance of the intracytoplasmic domain of the simian immunodeficiency virus (SIV) Env glycoprotein for pathogenesis. Abstract for 13th Annual Symposium on Nonhuman Primate Models for AIDS, Monterey California, p.190
46. Whatmore AM, Cook N, Hall GA, Sharpe S, Rud EW, Cranage MP (1995). Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol 69:5117-5123
47. Hoch J, Lang SM, Weeger M, Stahl-Hennig C, Coulibaly C, Dittmer U, Hunsmann G, Fuchs D, Mueller J, Sopper S, Fleckenstein B, Ueberla KT (1995) vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol 69:4807-4813
48. Hayward WS, Neel BG, Astrin SM (1981) Activation of cellular oncogene by promoter insertion in ALV-induced lymphoid leukosis. Nature 290:475-480
49. Desrosiers RC (1994) Letter to the Editor: Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine. AIDS Res Human Retroviruses 10:331-332
50. Ho DD, Cao Y (1995). Letter to the Editor. Long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 332:1647-1648
51. Blower SM, McLean AR (1994) Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 265:1451-1454